122 related articles for article (PubMed ID: 29050782)
1. Development of a peptide-based inducer of protein degradation targeting NOTCH1.
Ohoka N; Misawa T; Kurihara M; Demizu Y; Naito M
Bioorg Med Chem Lett; 2017 Nov; 27(22):4985-4988. PubMed ID: 29050782
[TBL] [Abstract][Full Text] [Related]
2.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
3. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
4. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
5. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
6. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
[TBL] [Abstract][Full Text] [Related]
7. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
Ohoka N; Shibata N; Hattori T; Naito M
Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
[TBL] [Abstract][Full Text] [Related]
8. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
Shibata N; Nagai K; Morita Y; Ujikawa O; Ohoka N; Hattori T; Koyama R; Sano O; Imaeda Y; Nara H; Cho N; Naito M
J Med Chem; 2018 Jan; 61(2):543-575. PubMed ID: 28594553
[TBL] [Abstract][Full Text] [Related]
9. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.
Ohoka N; Tsuji G; Shoda T; Fujisato T; Kurihara M; Demizu Y; Naito M
ACS Chem Biol; 2019 Dec; 14(12):2822-2832. PubMed ID: 31580635
[TBL] [Abstract][Full Text] [Related]
10. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
12. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
Demizu Y; Shibata N; Hattori T; Ohoka N; Motoi H; Misawa T; Shoda T; Naito M; Kurihara M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4865-4869. PubMed ID: 27666635
[TBL] [Abstract][Full Text] [Related]
13. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
14. Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative.
Tomoshige S; Nomura S; Ohgane K; Hashimoto Y; Ishikawa M
Bioorg Med Chem Lett; 2018 Feb; 28(4):707-710. PubMed ID: 29366651
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis targeting peptide (PROTAP) strategy for protein ubiquitination and degradation.
Zheng J; Tan C; Xue P; Cao J; Liu F; Tan Y; Jiang Y
Biochem Biophys Res Commun; 2016 Feb; 470(4):936-40. PubMed ID: 26826379
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1).
Blankenship JW; Varfolomeev E; Goncharov T; Fedorova AV; Kirkpatrick DS; Izrael-Tomasevic A; Phu L; Arnott D; Aghajan M; Zobel K; Bazan JF; Fairbrother WJ; Deshayes K; Vucic D
Biochem J; 2009 Jan; 417(1):149-60. PubMed ID: 18939944
[TBL] [Abstract][Full Text] [Related]
17. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
[TBL] [Abstract][Full Text] [Related]
18. Development of a peptide-based inducer of nuclear receptors degradation.
Demizu Y; Ohoka N; Nagakubo T; Yamashita H; Misawa T; Okuhira K; Naito M; Kurihara M
Bioorg Med Chem Lett; 2016 Jun; 26(11):2655-8. PubMed ID: 27086122
[TBL] [Abstract][Full Text] [Related]
19. The intracellular domain of Jagged-1 interacts with Notch1 intracellular domain and promotes its degradation through Fbw7 E3 ligase.
Kim MY; Jung J; Mo JS; Ann EJ; Ahn JS; Yoon JH; Park HS
Exp Cell Res; 2011 Oct; 317(17):2438-46. PubMed ID: 21820430
[TBL] [Abstract][Full Text] [Related]
20. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
